Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

NCT07216248 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: relugolix + ARPI
DRUG: Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI
DRUG: relugolix or androgen deprivation therapy (ADT) + ARPI
DRUG: relugolix + ARPI.

Sponsor

University of Utah